Certain Notch Pathway Genes Predict Survival in Cutaneous Melanoma
the Cancer Therapy Advisor take:
Cutaneous melanoma disease-specific survival may be predicted by the SNPs in Notch pathway genes, according to a study published online in Cancer Epidemiology, Biomarkers & Prevention.
The Notch signaling pathway promotes growth and aggressive metastatic potential of primary melanoma cells in human cutaneous melanoma.
In the study, 6,256 SNPs were identified in 48 Notch pathway genes in 858 patients with cutaneous melanoma who were previously included in a cutaneous melanoma genome-wide association dataset.
Results revealed four putative functional SNPs of Notch genes were both independently and jointly associated with predictive roles in survival of patients with cutaneous melanoma. The variant with the most significant predictive role was NCOR2 rs2342924 T>C (aHR= 2.71; 95% CI: 1.73, 4.23; Ptrend=9.62 × 10−7). The other three predictive SNPs were NCSTN rs1124379 G>A (Ptrend=0.005), NCOR2 rs10846684 G>A (Ptrend=0.005), and MAML2 rs7953425 G>A (Ptrend=0.013).
When using the receiver operating characteristic analysis curve, the area under the curve was significantly greater after adding the unfavorable genotype score to the model containing the identified clinicopathologic factors.
The study’s findings suggest that a potential exists for developing an improved prognostic assessment and personalized management approach for patients with cutaneous melanoma using these identified genetic variants as a genotype score of biomarkers.
Cutaneous melanoma disease-specific survival may be predicted by the SNPs in Notch pathway genes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer